Delayed onset of paresis in rats with experimental intramedullary spinal cord gliosarcoma following intratumoral administration of the paclitaxel delivery system OncoGel: Laboratory investigation

Journal of Neurosurgery: Spine

Volumn 16, Issue 1, 2012, Pages 93-101

  Tyler, Betty M ^a   Hdeib, Alia ^a   Caplan, Justin ^a   Legnani, Federico G ^a,b   Fowers, Kirk D ^c   Brem, Henry ^a   Jallo, George ^a   Pradilla, Gustavo ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c BIOCOMPATIBLES UK LTD   (United Kingdom)

Author keywords

Gliosarcoma; Intramedullary spinal cord tumor; OncoGel chemotherapy; Oncology; Paclitaxel; Rat

Indexed keywords

PACLITAXEL; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASSO BEATTIE BRESNAHAN RATING SCALE; BIODEGRADABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; FEMALE; GEL; GLIOSARCOMA; HISTOPATHOLOGY; INJECTION; INTRAMEDULLARY INJECTION; INTRAMEDULLARY SPINAL CORD GLIOSARCOMA; MOTOR PERFORMANCE; NONHUMAN; PARESIS; RAT; RATING SCALE; SURVIVAL; TOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; GELS; GLIOSARCOMA; PACLITAXEL; PARESIS; RATS; RATS, INBRED F344; SPINAL CORD NEOPLASMS;

EID: 84855412113     PISSN: 15475654     EISSN: 15475646     Source Type: Journal    
DOI: 10.3171/2011.9.SPINE11435     Document Type: Article

References (51)

1. Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, et al: Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 15:2887-2893, 2008
2. Bagley CA, Bookland MJ, Pindrik JA, Ozmen T, Gokaslan ZL, Witham TF: Local delivery of oncogel delays paresis in rat metastatic spinal tumor model. J Neurosurg Spine 7:194-198, 2007 (Pubitemid 47219753)
3. Balmaceda C: Chemotherapy for intramedullary spinal cord tumors. J Neurooncol 47:293-307, 2000
4. Basso DM, Beattie MS, Bresnahan JC: A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 12:1-21, 1995
5. Basso DM, Beattie MS, Bresnahan JC, Anderson DK, Faden AI, Gruner JA, et al: MASCIS evaluation of open field locomotor scores: effects of experience and teamwork on reliability. Multicenter Animal Spinal Cord Injury Study. J Neurotrauma 13:343-359, 1996 (Pubitemid 26405758)
6. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008-1012, 1995
7. Buda A, Floriani I, Rossi R, Colombo N, Torri V, Conte PF, et al: Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group. Br J Cancer 90:2112-2117, 2004 (Pubitemid 38877624)
8. Caplan J, Pradilla G, Hdeib A, Tyler BM, Legnani FG, Bagley CA, et al: A novel model of intramedullary spinal cord tumors in rats: functional progression and histopathological characterization. Neurosurgery 59:193-200, 2006
9. Carpentier AF: Neuro-oncology: the growing role of chemotherapy in glioma. Lancet Neurol 4:4-5, 2005
10. Chang SM, Kuhn JG, Robins HI, Schold SC Jr, Spence AM, Berger MS, et al: A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report. Cancer 91:417-422, 2001 (Pubitemid 32099244)
11. Delfino C, Caccia G, Gonzáles LR, Mickiewicz E, Rodger J, Balbiani L, et al: Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer. Oncology 66:18-23, 2004 (Pubitemid 38410675)
12. Gallia GL, Brem S, Brem H: Local treatment of malignant brain tumors using implantable chemotherapeutic polymers. J Natl Compr Canc Netw 3:721-728, 2005 (Pubitemid 44265417)
13. Garcia AA, O'Meara A, Bahador A, Facio G, Jeffers S, Kim DY, et al: Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer. Gynecol Oncol 93:493-498, 2004 (Pubitemid 38507624)
14. Glantz MJ, Choy H, Kearns CM, Mills PC, Wahlberg LU, Zuhowski EG, et al: Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst 87:1077-1081, 1995
15. Gok B, McGirt MJ, Sciubba DM, Garces-Ambrossi G, Nelson C, Noggle J, et al: Adjuvant treatment with locally delivered OncoGel delays the onset of paresis after surgical resection of experimental spinal column metastasis. Neurosurgery 65: 193-200, 2009
16. Guppy AE, Nelstrop AE, Foster T, Agarwal R, Seckl MJ, Rustin GJ: A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer. Br J Cancer 90:810-814, 2004 (Pubitemid 38406591)
17. Hagiwara H, Sunada Y: Mechanism of taxane neurotoxicity. Breast Cancer 11:82-85, 2004
18. Jallo GI, Freed D, Epstein F: Intramedullary spinal cord tumors in children. Childs Nerv Syst 19:641-649, 2003 (Pubitemid 37184505)
19. Jallo GI, Kothbauer KF, Epstein FJ: Intrinsic spinal cord tumor resection. Neurosurgery 49:1124-1128, 2001 (Pubitemid 32995850)
20. Lapidus RG, Dang W, Rosen DM, Gady AM, Zabelinka Y, O'Meally R, et al: Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation. Prostate 58:291-298, 2004 (Pubitemid 38168927)
21. Lesniak MS, Brem H: Targeted therapy for brain tumours. Nat Rev Drug Discov 3:499-508, 2004 (Pubitemid 38807532)
22. Li KW, Dang W, Tyler BM, Troiano G, Tihan T, Brem H, et al: Polilactofate microspheres for Paclitaxel delivery to central nervous system malignancies. Clin Cancer Res 9:3441-3447, 2003 (Pubitemid 37082742)
23. Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, Nass D, et al: Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 100:472-479, 2004 (Pubitemid 38269075)
24. Lonardi S, Tosoni A, Brandes AA: Adjuvant chemotherapy in the treatment of high grade gliomas. Cancer Treat Rev 31:79-89, 2005 (Pubitemid 40542887)
25. Mardor Y, Rahav O, Zauberman Y, Lidar Z, Ocherashvilli A, Daniels D, et al: Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring. Cancer Res 65:6858-6863, 2005 (Pubitemid 41065083)
26. Marucci L, Niemierko A, Liebsch NJ, Aboubaker F, Liu MC, Munzenrider JE: Spinal cord tolerance to high-dose fractionated 3D conformal proton-photon irradiation as evaluated by equivalent uniform dose and dose volume histogram analysis. Int J Radiat Oncol Biol Phys 59:551-555, 2004
27. McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, et al: Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. Clinical article. J Neurosurg 110:583-588, 2009
28. Nieto Y, Vaughan WP: Pharmacokinetics of high-dose chemotherapy. Bone Marrow Transplant 33:259-269, 2004 (Pubitemid 38256557)
29. Parsa AT, Lee J, Parney IF, Weinstein P, McCormick PC, Ames C: Spinal cord and intradural-extraparenchymal spinal tumors: current best care practices and strategies. J Neurooncol 69:291-318, 2004 (Pubitemid 39256136)
30. Pennant WA, Sciubba DM, Noggle JC, Tyler BM, Tamargo RJ, Jallo GI: Microsurgical removal of intramedullary spinal cord gliomas in a rat spinal cord decreases onset to paresis, an animal model for intramedullary tumor treatment. Childs Nerv Syst 24:901-907, 2008
31. Pipas JM, Meyer LP, Rhodes CH, Cromwell LD, McDonnell CE, Kingman LS, et al: A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. J Neurooncol 71:301-305, 2005 (Pubitemid 40372961)
32. Poirier VJ, Hershey AE, Burgess KE, Phillips B, Turek MM, Forrest LJ, et al: Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors. J Vet Intern Med 18:219-222, 2004 (Pubitemid 38393633)
33. Pradilla G, Wang PP, Gabikian P, Li K, Magee CA, Walter KA, et al: Local intracerebral administration of Paclitaxel with the paclimer delivery system: toxicity study in a canine model. J Neurooncol 76:131-138, 2006 (Pubitemid 43135845)
34. Raza SM, Pradilla G, Legnani FG, Thai QA, Olivi A, Weingart JD, et al: Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours. Expert Opin Biol Ther 5:477-494, 2005 (Pubitemid 40593332)
35. Recinos VR, Tyler BM, Bekelis K, Sunshine SB, Vellimana A, Li KW, et al: Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. Neurosurgery 66:530-537, 2010
36. Rose WC: Taxol: a review of its preclinical in vivo antitumor activity. Anticancer Drugs 3:311-321, 1992
37. Rowinsky EK, Donehower RC: Paclitaxel (taxol). N Engl J Med 332:1004-1014, 1995
38. Sandalcioglu IE, Gasser T, Asgari S, Lazorisak A, Engelhorn T, Egelhof T, et al: Functional outcome after surgical treatment of intramedullary spinal cord tumors: experience with 78 patients. Spinal Cord 43:34-41, 2005 (Pubitemid 40116467)
39. Shrivastava RK, Epstein FJ, Perin NI, Post KD, Jallo GI: Intramedullary spinal cord tumors in patients older than 50 years of age: management and outcome analysis. J Neurosurg Spine 2:249-255, 2005
40. Sipos EP, Brem H: Local anti-angiogenic brain tumor therapies. J Neurooncol 50:181-188, 2000 (Pubitemid 32166300)
41. Sipos EP, Tyler B, Piantadosi S, Burger PC, Brem H: Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol 39:383-389, 1997 (Pubitemid 27078122)
42. Tishler RB, Schiff PB, Geard CR, Hall EJ: Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22:613-617, 1992
43. Townsend N, Handler M, Fleitz J, Foreman N: Intramedullary spinal cord astrocytomas in children. Pediatr Blood Cancer 43:629-632, 2004 (Pubitemid 39411218)
44. Tyler B, Fowers KD, Li KW, Recinos VR, Caplan JM, Hdeib A, et al: A thermal gel depot for local delivery of paclitaxel to treat experimental brain tumors in rats. Laboratory investigation. J Neurosurg 113:210-217, 2010
45. Van Goethem JW, van den Hauwe L, Ozsarlak O, De Schepper AM, Parizel PM: Spinal tumors. Eur J Radiol 50:159-176, 2004 (Pubitemid 38469967)
46. Vogelbaum MA: Convection enhanced delivery for the treatment of malignant gliomas: symposium review. J Neurooncol 73:57-69, 2005 (Pubitemid 40823269)
47. Walter KA, Cahan MA, Gur A, Tyler B, Hilton J, Colvin OM, et al: Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res 54:2207-2212, 1994 (Pubitemid 24138696)
48. Werner-Wasik M, Yu X, Marks LB, Schultheiss TE: Normal-tissue toxicities of thoracic radiation therapy: esophagus, lung, and spinal cord as organs at risk. Hematol Oncol Clin North Am 18:131-160, x-xi, 2004
49. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, et al: Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 22:2061-2068, 2004 (Pubitemid 41095138)
50. Wist EA, Sommer HH, Ostenstad B, Risberg T, Fjaestad K: Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. Acta Oncol 43:11-14, 2004 (Pubitemid 38283167)
51. Zentner GM, Rathi R, Shih C, McRea JC, Seo MH, Oh H, et al: Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release 72:203-215, 2001 (Pubitemid 32522358)